BALB/c, SJL/J, and C57BL/6 mice injected intraperitoneally with pristane develop lupus-specific autoantibodies, including anti-nRNP/Sm and ribosomal P, as well as the less disease-specific autoantibodies anti-Su, histone, and single-stranded (ss)DNA ([@B1]--[@B3]). They also develop severe immune complex--mediated glomerulonephritis starting 4--6 mo after pristane treatment ([@B2], [@B3]). Anti--double-stranded (ds)DNA antibodies, which are implicated in the pathogenesis of lupus nephritis ([@B4], [@B5]), have so far not been observed, raising questions about the role of anti-dsDNA antibodies in the development of nephritis in these mice.

IL-6 production by an expanded macrophage compartment is thought to be instrumental in the pathogenesis of anti-DNA antibodies and nephritis in (NZB/W)F1 mice ([@B6], [@B7]). In light of these findings and the fact that large amounts of IL-6 are produced upon uptake of pristane by murine peritoneal macrophages ([@B8], [@B9]), we investigated the role of this cytokine in autoantibody production in pristane-induced lupus. Our data indicate that production of IgG anti-ssDNA, antichromatin and anti-dsDNA antibodies in pristane-treated mice requires IL-6, suggesting that anti-DNA antibody production in lupus is a marker of IL-6 overproduction. Unexpectedly, the frequencies of anti-nRNP/Sm and Su autoantibodies were similar in IL-6 deficient versus intact mice, suggesting that pristane induces autoantibody production by both IL-6--independent and --dependent pathways.

Materials and Methods {#MaterialsMethods}
=====================

Mice.
-----

Mice were generated by five backcrosses of B6/129SV IL-6^−/−^ with BALB/cAn. Mice heterozygous for the IL-6 mutation were intercrossed to create IL-6^−/−^ and IL-6^+/+^ mice and were genotyped by Southern blotting ([@B10]). Female BALB/cAn IL-6^−/−^ (*n* = 28) and IL-6^+/+^ (*n* = 26) mice, age 10--12 wk, were injected once intraperitoneally with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane; Sigma Chemical Co., St. Louis, MO) ([@B1]). Control mice (IL-6^−/−^, *n* = 10 and IL-6^+/+^, *n* = 10) received 0.5 ml of PBS intraperitoneally. Sera were collected from the tail vein before treatment, at 3 wk, and at 3, 5, and 8 mo after treatment. Mice were housed under specific pathogen--free conditions.

Immunoprecipitation.
--------------------

Analysis of autoantibody specificities by immunoprecipitation was carried out as described previously ([@B1]).

ELISAs.
-------

Antigen capture ELISAs for anti-nRNP/Sm and anti-Su antibodies were performed as described, using mouse sera at a dilution of 1:500 and goat anti--mouse IgG second antibodies (γ chain--specific, from Southern Biotechnology Associates, Birmingham, AL) ([@B11], [@B12]). Anti-ssDNA ELISA was performed as previously described ([@B13]), and data were analyzed using the Mann Whitney test.

Anti-dsDNA antibody ELISA was carried out as previously described with minor modifications ([@B14]). In brief, calf thymus DNA (Sigma Chemical Co.) was extracted with phenol/chloroform/isoamyl alcohol and digested with S1 nuclease (GIBCO BRL, Gaithersburg, MD). Dynex polystyrene microtiter plates (Dynastar, Dynatech, Chantilly, VA) were coated with 100 μl/ well of 5 μg/ml DNA in SSC, pH 8.0, and incubated at 37°C for 12 h. Sera were tested at a 1:160 dilution followed by alkaline phosphatase--conjugated goat anti--mouse IgG antibodies. Substrate was added, and A~405\ nm~ was determined. Absorbances from blank wells (no serum added) were subtracted.

IgG antichromatin antibodies were measured as previously described ([@B15]). In brief, polyvinyl chloride microtiter plates were coated with 10 μg/ml chicken erythrocyte chromatin in borate-buffered saline. Sera were tested at a 1:500 dilution, followed by biotinylated goat anti--mouse IgG (pFc′-specific, 1:4,000 dilution, from Dr. P.L. Cohen, University of North Carolina, Division of Rheumatology and Immunology), avidin-conjugated alkaline phosphatase (Zymed Labs, South San Francisco, CA), and *p*-nitrophenyl phosphate substrate. The A~405\ nm~ of a 1:1,000 dilution of a high titer MRL/*lpr* reference serum was assigned a value of 2,048 units, and a 2^11^-fold dilution of this standard a value of 2 units ([@B15]). IgG antichromatin activity in units for each sample was determined as in reference [@B12].

Fluorescence Assay for Anti-dsDNA Antibodies.
---------------------------------------------

Anti-dsDNA antibodies were measured by the *Crithidia luciliae* kinetoplast staining assay ([@B16]) at a serum dilution of 1:20 according to the manufacturer\'s instructions (The Binding Site, Birmingham, UK). Second antibody was FITC-conjugated goat anti--mouse IgG (1:40 dilution; Southern Biotechnology Associates). All positive sera were titered (1:40, 1:80, 1:160, 1:320, and 1:640 dilutions).

Results and Discussion {#ResultsDiscussion}
======================

IL-6 has been implicated in both anti-DNA antibody production and the pathogenesis of nephritis in (NZB/ W)F1 mice ([@B6], [@B7]), and in the development of autoantibodies in patients with cardiac myxomas ([@B17], [@B18]). It also is essential for the growth of plasmacytomas in pristane-treated mice ([@B8], [@B19]--[@B21]). This study was undertaken to evaluate the role of this cytokine in the induction of autoantibodies by pristane in BALB/c mice.

Anti-DNA Antibody Production in Pristane-induced Lupus.
-------------------------------------------------------

The production of IgM anti-ssDNA antibodies 2--3 wk after treating BALB/c mice with pristane ([@B2]) appears to be thymus-independent (reference [@B2] and Richards, H.B., M. Satoh, J.C. Jennette, T. Okano, Y.S. Kanwar, and W.H. Reeves, manuscript submitted for publication). Because IL-6 can stimulate T cell--independent Ig production ([@B22], [@B23]), the induction of IgM anti-ssDNA antibodies by pristane in BALB/cAn IL-6^−/−^ and IL-6^+/+^ mice was investigated.

As shown in Fig. [1](#F1){ref-type="fig"}, IgM anti-ssDNA antibody levels were similar in IL-6^−/−^ versus IL-6^+/+^ mice 3 wk after pristane treatment. In contrast, IgG anti-ssDNA antibodies were detected at a high frequency 8 mo after pristane treatment only in IL-6^+/+^ mice (*P* \< 0.05 versus IL-6^−/−^ by Mann Whitney test).

Anti-dsDNA antibodies are highly specific for lupus and are implicated in the pathogenesis of lupus nephritis. However, they were not detected previously in the 6-mo sera from pristane-treated BALB/c mice, a time when severe renal lesions already were apparent ([@B2]). In contrast, sera from 10 out of 26 BALB/cAn (IL-6^+/+^) mice (38%) 8 mo after pristane treatment were strongly positive for anti- dsDNA antibodies by *Crithidia luciliae* kinetoplast staining (Table [1](#T1){ref-type="table"}) at titers ranging from 1:80 to 1:640 (Table [2](#T2){ref-type="table"}). Anti-dsDNA antibodies were not detected in pristane-treated IL-6^−/−^ mice or PBS-treated IL-6^+/+^ or IL-6^−/−^ mice (Table [1](#T1){ref-type="table"}). Although the *Crithidia luciliae* kinetoplast staining assay is highly specific for anti-dsDNA activity, occasionally antihistone antibodies give a false positive reaction. To exclude that possibility, the sera were tested for IgG anti-dsDNA antibodies by ELISA. The ELISA was somewhat less sensitive than the fluorescence assay, since only sera with titers \>1:640 gave a significantly stronger reaction by ELISA than the *Crithidia*-negative group. An anti-ssDNA mAb (6/O2 576-2; from Dr. D. Pisetsky, Duke University, Durham, NC) also showed weak ELISA reactivity. Remarkably, none of the sera from pristane-treated IL-6^−/−^ mice bound to S1 nuclease-treated DNA at 8 mo (Fig. [1](#F1){ref-type="fig"}).

Together, these results indicate that pristane-treated BALB/cAn mice develop high levels of IgG anti-ssDNA and anti-dsDNA antibodies, and that these autoantibodies are IL-6 dependent. However, the appearance of these autoantibodies is delayed until 8 mo after treatment, which is after the onset of renal disease. Some of the pristane-treated BALB/cAn mice developed IgG anti-dsDNA antibodies at levels comparable to those in MRL/*lpr* mice (Table [2](#T2){ref-type="table"}, Fig. [1](#F1){ref-type="fig"}). Although it has been suggested that anti-dsDNA antibody production can result from polyclonal B cell activation ([@B24]), the marked polyclonal hypergammaglobulinemia seen in both IL-6^+/+^ and IL-6^−/−^ mice 3--5 mo after pristane treatment was not accompanied by an anti-dsDNA response, suggesting that other mechanisms may be more important in generating these autoantibodies. These may include effects of IL-6 on terminal B cell differentiation ([@B17], [@B25]).

IgG Antichromatin Antibodies.
-----------------------------

Like anti-dsDNA, antichromatin antibodies are found at high levels in MRL/*lpr* and other lupus mice ([@B15], [@B26]). Anti-DNA responses are linked to the immune response to chromatin, since T cells specific for histones can help B cells producing anti-DNA antibodies ([@B27]). Thus, it was of interest to see if antichromatin and anti-DNA antibodies exhibit similar IL-6 dependence. Pristane induced high levels of IgG antichromatin antibodies within 3--5 mo, but only in BALB/cAn IL-6^+/+^ mice (Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, *C* and *D*). Interestingly there was low level spontaneous production of these autoantibodies in aged IL-6^+/+^ PBS-treated mice (Fig. [2](#F2){ref-type="fig"}), which was absent in IL-6^−/−^ animals. Thus, IL-6 may be important for the production of pristane-induced, as well as spontaneous, IgG antichromatin autoantibodies.

Since IL-6 plays an important role in the differentiation of antigen plus CD40 coactivated B cells into antibody- secreting cells ([@B28]), the lack of IgG anti-DNA/chromatin autoantibodies in IL-6-deficient mice may reflect an absolute requirement for IL-6 in the differentiation of germinal center B cells into anti-DNA/chromatin secreting plasma cells. This interpretation is consistent with previous observations that IL-6 is crucial for the development of anti-DNA/chromatin antibodies in spontaneous murine lupus models ([@B6], [@B7]) and that the production of these autoantibodies also is dependent on CD40--CD40 ligand interactions ([@B29], [@B30]). Rheumatoid factor is not produced in CD40 ligand--deficient MRL/*lpr* mice either, whereas anti-nRNP/Sm antibodies are ([@B30]), suggesting that the latter may be regulated differently than anti-DNA and rheumatoid factor. Like anti-dsDNA, rheumatoid factor was induced by pristane in IL-6^+/+^ but not IL-6^−/−^ mice (data not shown), suggesting that similar regulatory mechanisms may exist in pristane-induced lupus.

IgG Anti-nRNP/Sm and Anti-Su Antibodies.
----------------------------------------

The IL-6 dependence of IgG anti-DNA and chromatin autoantibodies is consistent with previous observations in the (NZB/ W)F1 lupus model ([@B6], [@B7]). However, (NZB/W)F1 do not produce other autoantibodies characteristic of lupus, such as anti-nRNP/Sm. Thus, it is not known whether or not the latter also are IL-6 dependent. This question was addressed in the pristane-induced lupus model, in which autoantibodies to both RNA-protein and DNA-protein autoantigens are produced.

In contrast to the absence of IgG anti-dsDNA and antichromatin autoantibodies and in IL-6^−/−^ mice (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, Table [1](#T1){ref-type="table"}), the frequencies of anti-nRNP/Sm autoantibodies were comparable in the IL-6^−/−^ and IL-6^+/+^ mice (Fig. [3](#F3){ref-type="fig"} *A*, Table [1](#T1){ref-type="table"}), although levels were lower in the IL-6^−/−^ mice (Fig. [3](#F3){ref-type="fig"} *B*). Similarly, the frequencies of anti-Su autoantibodies in IL-6^+/+^ versus IL-6^−/−^ mice were comparable (Table [1](#T1){ref-type="table"}). In agreement with the ELISA data, both anti-nRNP/Sm and anti-Su autoantibodies were detectable in the sera of IL-6^−/−^ by immunoprecipitation of ^35^S-labeled cell extracts. We conclude that the induction of anti-nRNP/Sm and Su autoantibodies is IL-6 independent, whereas their levels are influenced by IL-6. Since IgG2a was the predominant isotype of the anti-nRNP/Sm and Su, as well as anti-dsDNA and -chromatin autoantibodies (not shown), it is unlikely that the differential effects of IL-6 on their induction reflects merely an altered ability to produce antibodies of a particular isotype or isotypes. Furthermore, analysis of total Ig levels revealed marked increases in IgG2a, IgG2b, and IgG3 from 1 to 3 mo after pristane treatment both in IL-6^+/+^ and IL-6^−/−^ mice (data not shown). This was only slightly less dramatic in the IL-6^−/−^ group than in the IL-6^+/+^ mice.

Although DNA binding is critical for the activation of a subset of anti-Sm B cells ([@B31]), our data argue that the induction of anti-DNA and anti-Sm responses may be at least partially independent processes. This also appears true in CD40 ligand--deficient mice ([@B30]). Whereas anti-DNA/chromatin is CD40 and IL-6 dependent, anti-nRNP/Sm antibody production may be enhanced via a T cell--dependent and CD40- and IL-6--independent mechanism (Richards, H.B., M. Satoh, J.C. Jennette, T. Okano, Y.S. Kanwar, and W.H. Reeves, et al., manuscript submitted for publication). Certain CD40 ligand--negative T cell clones retain the capacity to induce plasma cell differentiation ([@B32]). Recently, it was shown that the CD27--CD70 signaling pathway may promote B cell differentiation into IgG-secreting plasma cells, whereas CD40 ligand--CD40 signaling may be more important for maintaining B cell proliferation and differentiation into memory cells ([@B33], [@B34]). The role of this or other pathways of CD40 ligand-- independent B cell activation in the generation of anti-nRNP/Sm and Su antibodies remains to be determined.

IL-6 is thought to influence the development of spontaneous human and murine lupus. It may play a role in the induction of autoantibodies ([@B17]) and nephritis ([@B35], [@B36]), as well as in polyclonal B cell activation ([@B37], [@B38]). Polyclonal hypergammaglobulinemia in lupus may reflect both the overexpression of IL-6 receptors on B cells ([@B37], [@B39]) and, in MRL/*lpr* mice, increasing IL-6 gene expression and serum levels with age ([@B40]). Although increased IL-6 production in MRL mice is related to the presence of the *lpr* gene, it is not produced by the abnormal double negative T cells ([@B40]), and may be derived from the expanded macrophage subset of these mice ([@B6], [@B41]).

Summary and Clinical Implications.
----------------------------------

The goal of this study was to examine the production of anti-dsDNA antibodies, long considered to be a marker of lupus nephritis ([@B4], [@B5]), in pristane-induced lupus. Anti-dsDNA antibodies were produced late in the course of pristane-induced lupus and were strictly IL-6 dependent, possibly reflecting the IL-6 overproduction characteristic of pristane-treated mice ([@B8], [@B9]). However, their onset at 8--11 mo after pristane treatment was well after the establishment of renal disease ([@B2]), arguing that the renal lesions may not be caused directly by anti-dsDNA antibodies. Nevertheless, renal disease in pristane-treated B6 IL-6^−/−^ mice is milder than in IL-6^+/+^ controls (Richards, H.B., M. Satoh, M. Shaw, C. Libert, V. Poli, and W.H. Reeves, unpublished data), consistent with the idea that IL-6 itself may contribute to the development of nephritis ([@B42]). Interestingly, although the levels of anti-nRNP/Sm antibodies also were influenced by IL-6, their frequency was not, suggesting that they may be regulated differently from anti-DNA antibodies.

The different cytokine requirements for anti-dsDNA and anti-Sm antibody production may help to explain differences in the patterns of their expression seen clinically. For example, low levels of antichromatin antibodies developed spontaneously in aged BALB/cAn^+/+^ mice but not in IL-6^−/−^ mice (Fig. [2](#F2){ref-type="fig"}), an observation that may be relevant to the increased frequency of antinuclear antibodies ([@B43]) and higher IL-6 production ([@B44]) in elderly people.

The extreme variability characteristic of anti-dsDNA antibody levels ([@B5]) contrasts with the fact that the levels of anti-Sm generally remain relatively stable over time. We speculate that, as in pristane-induced lupus, anti-dsDNA antibody production in human SLE may be IL-6 dependent. Thus, anti-dsDNA/chromatin antibody levels might be a surrogate marker for increased IL-6 production, which is associated with active SLE ([@B37]). The induction of anti-DNA antibodies in mice by lipopolysaccharide ([@B45]), a potent inducer of IL-6 ([@B46]), raises the possibility that microbial stimulation could trigger both IL-6 production and anti-DNA autoantibody production. Indeed, pristane- induced lupus is milder in specific pathogen--free than in conventionally housed mice ([@B12]). In view of the importance of anti-DNA antibodies and IL-6 in lupus nephritis, it may be of interest to examine the role of microbial stimulation of IL-6 production in the pathogenesis of lupus flares.
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###### 

Anti-ssDNA and anti-dsDNA autoantibody levels. (*left*) Sera from BALB/cAn IL-6^−/−^ or IL-6^+/+^ mice 3 wk after pristane or PBS treatment were tested by ELISA for IgM anti-ssDNA antibodies at a dilution of 1:500. Sera from the same mice 8 mo after treatment were tested by ELISA for IgG anti-ssDNA antibodies. Symbols represent individual animals and horizontal lines represent the mean A~405\ nm~ of each group (\**P* \< 0.005 in the IL-6^+/+^ pristane versus IL-6^−/−^ pristane by Mann Whitney test). (*right*) Sera from BALB/cAn mice 8 mo after pristane or PBS treatment, 5-mo-old MRL/*lpr* mice, and mAb 6/O2 576-2 (IgG anti-ssDNA) were analyzed by ELISA for IgG anti-dsDNA antibodies at a 1:160 dilution. Samples were negative (•) or positive (□) positive by *Crithidia* assay at a 1:40 dilution.
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Frequency of Autoantibodies in Pristane-treated BALB/cAN Mice

  Strain and Rx           No. of mice      Anti- nRNP/Sm[\*](#TF1-150){ref-type="table-fn"}      Anti-Su[\*](#TF1-150){ref-type="table-fn"}      Anti- dsDNA[\*](#TF1-150){ref-type="table-fn"}
  -------------------- -- ------------- -- -------------------------------------------------- -- -------------------------------------------- -- ------------------------------------------------
  IL-6^−/−^ pristane      28               13 (46%)                                              10 (36%)                                        0
  IL-6^−/−^ PBS           10               0                                                     0                                               0
  IL-6^+/+^ pristane      26               15 (58%)                                              8 (31%)                                         10 (38%)
  IL-6^+/+^ PBS           10               0                                                     0                                               0

Sera from BALB/cAn mice were tested 8 mo after treatment with pristane or PBS. Anti-nRNP/Sm and Su antibodies were detected by immunoprecipitation and their presence was confirmed by ELISA (Fig. [3](#F3){ref-type="fig"}). Anti-dsDNA antibodies were detected in the sera by *Crithidia luciliae* kinetoplast staining at a dilution of 1:20.  

###### 

Titers of Anti-dsDNA Antibodies in Pristane-treated BALB/cAN IL-6^+/+^ Mice[\*](#TF2-150){ref-type="table-fn"}

  Titer       No. of mice
  -------- -- -------------
  1:80        1
  1:160       4
  1:320       2
  ≥1:640      3

*Crithidia luciliae* kinetoplast staining assay.  

![Anti-nRNP/Sm and anti-chromatin antibody ELISAs.Sera from pristane treated IL-6^−/−^ (*n* = 28, •) or IL-6^+/+^ (*n* = 26, ▪) mice and from PBS-treated IL-6^−/−^ (*n* = 10, ○) or IL-6^+/+^ (*n* = 10, □) mice 0--8 mo after treatment were tested for anti-nRNP/Sm (*A* and *B*) and antichromatin (*C* and *D*) antibodies by ELISA. (*Top*) Frequencies (%) of sera containing IgG anti-nRNP/Sm (*A*) or antichromatin (*B*) autoantibodies (defined as \>3 SDs above the mean of negative controls). (*Bottom*) Levels of anti-nRNP/Sm (*B*) or anti-chromatin (*D*) autoantibodies (in units). Data represent the mean of all animals in each group.](JEM980733.f3){#F3}

![IgG antichromatin antibody ELISA. Serial serum samples from all pristane- or PBS-treated mice were analyzed at a dilution of 1:500 for IgG anti-chromatin antibodies by ELISA. Levels of IgG antichromatin are expressed in units × 10^6^ (see Materials and Methods).](JEM980733.f2){#F2}
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